All News

A panel of pharmacists and nurse practitioners discussed how interdisciplinary diabetes teams divide technology education, medication management, and follow-up care.

Pharmacists proactively identify red flags for early detection, navigate complex insurance and access barriers for high-cost disease-modifying therapies, and serve as educators across settings.

Patients with cancer on semaglutide or tirzepatide face hidden drug-drug interactions such as slowed absorption and nausea, requiring antiemetics and pharmacist coordination.

The 20-mg once-daily tablet is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C).

Prepare your pharmacy for flu season with updated vaccine formulations, screening, staffing, ordering, cold-chain controls, billing workflows, and patient outreach to boost vaccination uptake.

Outpatient BiTE therapy for multiple myeloma may be safely supported in community oncology settings through careful patient selection, pharmacist-led coordination, home monitoring, caregiver education, and standardized protocols for managing CRS and ICANS.

Explore emerging flu antivirals, from season-long CD388 prevention to single-dose therapies, designed to beat current treatment limits.

If approved, AXS-12 would be a potentially valuable new option for a symptom that significantly impairs the daily functioning of those with narcolepsy.

Compared with conventional imaging alone, patient-reported outcomes integrated with machine learning may provide an earlier indication of breast cancer recurrence, disease progression, and survival.

Get engaged or get left out.

In an interview with Pharmacy Times, Nicole McMullin, regional clinical pharmacist at American Oncology Network, discussed AON’s development of an all-outpatient approach to step-up dosing for bispecific T-cell engager therapy in multiple myeloma.

An expert discusses a JAMA study that shows who depends on the MMRV combination vaccine and how policy shifts may widen gaps—plus how pharmacists keep children on schedule.

In an interview with Pharmacy Times, Manale Maksour, PharmD, BCOP, BCPS, associate director of pharmacy services at American Oncology Network, discusses the growing use of outpatient step-up dosing for bispecific T-cell engager therapies and the operational challenges clinics must address to safely implement these programs.

Future research should evaluate larger multicenter experiences and assess if pharmacist-supported workflows are associated with treatment persistence, safety monitoring adherence, and clinical outcomes.

TV-44749 is a subcutaneous long-acting injectable form of olanzapine that is effective in schizophrenia while avoiding risks seen with the intramuscular formulation.

Pharmacist-led pathways, multimodal analgesia, and patient-centered opioid stewardship may help improve acute pain management while balancing opioid safety, adequate pain relief, and access to emerging nonopioid options.

The approval of the drug combination is supported by findings from the phase 3 VIKTORIA-1 clinical trial.

Case counts will likely continue to rise as reporting catches up with the incubation lag.

Selpercatinib received approval for adults and children 2 years and older with previously treated or treatment-refractory RET fusion–positive solid tumors.

Clinicians can mitigate anemia during cancer treatment by reducing the dose, switching to alternate-day dosing, or providing growth factor support.

In an interview with Pharmacy Times, Brandon Kasberg, PharmD, discusses how pharmacists can help individualize multimodal acute pain regimens, reduce unnecessary opioid exposure, and support safer transitions from inpatient or postoperative care to the outpatient setting.

This FAQ breaks down which drugs are covered by the program, who qualifies, how to process claims correctly, and what pharmacists need to know to counsel patients through this landmark shift in obesity drug access.

Emerging data on psychedelics demonstrate efficacy in preventing cluster headaches.

AI reshapes pharmacy—see how stewardship, transparency, and training help pharmacists deploy tools safely, boost equity, and build trust.

This approval marks the first time patients can begin treatment with home administration either by themselves or their caregiver.

Like other HCPs, pharmacists use AI-driven tools to support the delivery of pharmacy-related services.

Pharmacist-driven discharge medication reconciliation services identifies clinical interventions and may contribute to a decreased 30-day readmission rate.

A member of the cardio-kidney-metabolic syndrome (CKM) guideline writing committee outlines steps pharmacists can take to ensure the kidney component of CKM is not overlooked.